Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Germany

European Research Council grant · Finished

iPYRO Custom-Made Designer Macrophages to Revolutionize the Safety of Parenteral Drugs

Coordinator
Medizinische Hochschule Hannover, Germany
Runs
1 January 2023 to 30 June 2024
Status
Finished
EU funding
€150k
Total cost
—
Partners
1 organisations in 1 countries
Type
European Research Council grant
Grant agreement
101100859

What the project is doing

In the project's own words, from its summary on CORDIS.

The iPYRO proposal is built upon the uniqueness of human induced pluripotent stem cells (iPSC) and recent innovations in the farming of fully defined human macrophages (iMonoMac) using industry compatible bioreactors. Given the growing need for industrial macrophages, iPYRO sets an innovation in the forefront of drug safety evaluations, supplying a unique cell type, which meets the expectations from industry and regulators.

The breakthrough innovation of iPYRO will offer a superior, thus highly standardized, economically produced and fully validated off-the-shelf macrophage-based cell product to revolutionize the safety of drugs and beyond. To maximize the outcome, iPYRO will assess the regulatory compliance, while further streamlining the iMonoMac product for the envisioned spinout, establishing a proper freedom-to-operate strategy and a suitable business model.

The seminal iMonoMac platform along the unique IPR and established contacts to industrial and regulatory stakeholders will pave the transition from academia to industry, introducing for the very first time an iPSC-cell product for the drug safety market market.

Topics

Who is involved

OrganisationCityCountryRole
Medizinische Hochschule HannoverHannoverGermanyCoordinator

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI